Previous close | 0.3300 |
Open | N/A |
Bid | 0.0000 |
Ask | 0.9500 |
Strike | 1.00 |
Expiry date | 2024-06-21 |
Day's range | 0.3300 - 0.3300 |
Contract range | N/A |
Volume | |
Open interest | 5 |
SOUTH SAN FRANCISCO, Calif., June 06, 2024--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant unmet medical need, announced that the San Francisco Business Times and the Silicon Valley Business Journal have recognized the company as a Best Place to Work in 2024.
SOUTH SAN FRANCISCO, Calif. & MUNICH, June 04, 2024--Spruce Biosciences, Inc. (Nasdaq: SPRB) ("Spruce"), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant unmet medical need, and HMNC Brain Health GmbH ("HMNC"), a global precision psychiatry biopharma company, announced today a strategic collaboration to develop Spruce’s investigational product candidate, tildacerfont, a second-generation CRF
SOUTH SAN FRANCISCO, Calif., June 03, 2024--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine disorders with significant unmet medical need, presented results from its Phase 2 POWER study of tildacerfont, a second-generation CRF1 receptor antagonist, for the treatment of polycystic ovary syndrome (PCOS) at the 2024 Annual Meeting of the Endocrine Society (ENDO 2024).